Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 9 - Stockholders' Equity (Details Textual)

Note 9 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions					1 Months Ended		3 Months Ended
	Apr. 22, 2024	Jun. 21, 2023 shares	Jun. 22, 2022 shares	Jun. 25, 2021 shares	Nov. 30, 2022 USD ($)	Aug. 31, 2021 USD ($)	Mar. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2020 shares
Common Stock, Shares Authorized (in shares)							3,750,000	3,750,000
Common Stock, Shares, Issued (in shares)							1,236,688	1,236,688
Common Stock, Shares, Outstanding (in shares)							1,236,688	1,236,688
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 0.001	$ 0.001
Preferred Stock, Shares Authorized (in shares)							10,000,000	10,000,000
Preferred Stock, Shares Issued (in shares)							15,617	15,617
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							15,617	15,617
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 0.001	$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							13.34
Jefferies L L C [Member] \| At the Market Offering [Member]
Sale of Stock, Authorized Amount \| $					$ 75	$ 50
Stock Issued During Period, Shares, New Issues (in shares)							0
Employee Director And Consultant Equity Incentive Plan2020 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)									43,750
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)									19,746
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)		75,000	37,500	28,125
The 2023 Employee Stock Purchase Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)							9,375
Series A Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)							85	85
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							85	85
Series B Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)							4,026	4,026
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							4,026	4,026
Series C Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)							3,506	3,506
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							3,506	3,506
Series D Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)							3,000	3,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							3,000	3,000
Series E Preferred Stock [Member]
Preferred Stock, Shares Issued (in shares)							5,000	5,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							5,000	5,000
Reverse Stock Split [Member] \| Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	80